Kalaris net loss widens to $11.52 million in Q2 FY26

Reuters2026/08/11 12:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Kalaris Therapeutics posted a GAAP net loss of USD 11.52 million, versus a GAAP net loss of USD 11.35 million a year earlier.
GAAP R&D expense rose 6.85% to USD 9.02 million, while GAAP G&A expense fell 11.74% to USD 3.37 million.
Cash, cash equivalents and marketable securities totaled USD 93.54 million, down from USD 117.98 million at Dec. 31, 2025.
Patient dosing continues in the Phase 1b/2 TH103 study; preliminary data is expected in 1H 2027, with Phase 3 initiation targeted by year-end 2027.
CEO Andrew Oxtoby cited new clinical-material batches with process enhancements, following expanded Phase 1a TH103 results supporting prior BCVA, OCT and PK findings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110800PRIMZONEFULLFEED9807147) on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Kalaris net loss widens to $11.52 million in Q2 FY26

You may also like

Crypto prices